SHANGHAI FUDAN-ZHANGJIANG BIO-PHARMACEUTICAL CO.,LTD.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

1349

CNE1000000W4

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-05-14 EDT			5-day change	1st Jan Change
2.22 ^HKD	-0.45%		+2.30%	-12.94%

04-29	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-22	Shanghai Fudan-Zhangjiang Buys Structured Deposits Worth 200 Million Yuan	MT

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024

April 29, 2024 at 05:02 am

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was CNY 147.65 million compared to CNY 189.15 million a year ago. Net income was CNY 2.35 million compared to CNY 8.79 million a year ago.

Latest news about Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
Shanghai Fudan-Zhangjiang Buys Structured Deposits Worth 200 Million Yuan	04-22	MT
Fudan-Zhangjiang Bio Sees Profit, Revenue Drop in 2023	03-31	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Proposes Final Ordinary Dividend for the Year Ended December 31, 2023, Payable on August 26, 2024	03-28	CI
Fudan-Zhangjiang Bio's 2023 Profit Falls	02-26	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	02-23	CI
Fudan-Zhangjiang Bio-Pharmaceutical to Subscribe for Deposit Products Worth 357 Million Yuan	01-04	MT
Fudan-Zhangjiang Invests 357 Million Yuan in Ping An Bank Structured Deposit Products	01-03	MT
Fudan-Zhangjiang Unit's Clinical Trial Application for Glioma Visualization Agent Accepted in China	12-27	MT
Chinese Regulator Accepts Fudan-Zhangjiang Bio-Pharmaceutical's Application for Bladder Cancer Visualization Drug Trial	12-18	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Receives the Acceptance Notice for the Application	12-18	CI
Chinese Regulator NMPA Grants Acceptance Notice for Shanghai Fudan-Zhangjiang's Investigational Drug	11-13	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Receives the Acceptance Notice for the Investigational New Drug	11-13	CI
Fudan-Zhangjiang Bio-Pharmaceutical's Cancer Drug Passes Chinese Regulator’s Consistency Evaluation	11-08	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Notification of Approval for Supplementary Drug Application	11-08	CI
Fudan-Zhangjiang's Profit Drops 70.5% in Q3	23-10-31	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Fudan-Zhangjiang Bio Gets Nod for Cancer Drug Trial	23-10-23	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Acceptance Notice Issued by the National Medical Products Administration of the PRC	23-10-20	CI
Fudan-Zhangjiang Bio Puchases Structured Deposit Products	23-10-12	MT
Fudan-Zhangjiang Bio Swings to Profit in H1	23-08-11	MT
Fudan-Zhangjiang Bio Enrolls First Patient in FZ-AD004 Clinical Trial	23-08-10	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Announces First Patient Enrolled in Phase I Clinical Trial of FZ-AD004 Antibody Drug Conjugate for the Treatment of Advanced Solid Tumors	23-08-09	CI
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-02	CI
Fudan-Zhangjiang Bio to Swing to H1 Profit	23-07-18	MT

Chart Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

Duration

Period

Chart Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

More charts

Company Profile

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is a China-based company mainly engaged in research and development, manufacturing and marketing of biomedicine. The Company's products include aminolevulinic acid hydrochloride topical powder (trade name: ALA) and hemporfin or injection (trade name: FuMeiDa), and doxorubicin hydrochloride liposome injection (trade name: LIBOd), among others. Its products are mainly used for skin venereal disease treatment and anti-tumor treatment. The Company conducts its businesses in the domestic market.

Sector

Pharmaceuticals

Calendar

2024-08-18 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
SHANGHAI FUDAN-ZHANGJIANG BIO-PHARMACEUTICAL CO.,LTD.	-12.94%	848M
MERCK KGAA	+15.09%	74.45B
KYOWA KIRIN CO. LTD.	+11.35%	9.18B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+54.35%	5.03B
SK BIOPHARMACEUTICALS CO., LTD.	-12.85%	5.02B
YUHAN CORPORATION	+1.60%	3.82B
BETTA PHARMACEUTICALS CO., LTD.	-20.85%	2.41B
INDIVIOR PLC	+16.88%	2.39B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.25%	2.27B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+24.62%	2.26B

Specialty & Advanced Pharmaceuticals